We are live on
!
Find out more
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Portfolio holdings
AUM
$73.6M
1-Year Est. Return
61.93%
This Fund
S&P 500
This Quarter
Est. Return
+18.96%
1 Year Est. Return
+61.93%
3 Year Est. Return
+167.56%
5 Year Est. Return
+341.85%
10 Year Est. Return
+2,192.73%
AUM
$65.6M
AUM Growth
+$579K
(+0.89%)
Cap. Flow
-$1.7M
Cap. Flow
% of AUM
-2.59%
Top 10 Holdings %
Top 10 Hldgs %
99.33%
Holding
12
New
2
Increased
2
Reduced
4
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$4.46M |
| 2 |
VRS
Verso Corporation
VRS
|
+$2.67M |
| 3 |
Euronet Worldwide
EEFT
|
+$1.08M |
| 4 |
Navigator Holdings
NVGS
|
+$354K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$4.67M |
| 2 |
Newmont
NEM
|
+$2.99M |
| 3 |
BNY
Bank of New York Mellon
BNY
|
+$1.1M |
| 4 |
Wells Fargo
WFC
|
+$755K |
| 5 |
IRIDEX
IRIX
|
+$748K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 34.81% |
| 2 | Materials | 26.16% |
| 3 | Energy | 25.32% |
| 4 | Financials | 5.42% |
| 5 | Technology | 1.58% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Newmont
NEM
$124B
| $12.1M | 18.37% |
200,000
-50,000
| -20% | -$2.99M |
|
|
2
Navigator Holdings
NVGS
$1.26B
| $11.2M | 17.09% |
1,260,000
+35,000
| +3% | +$354K |
|
|
RETA
3
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $9.97M | 15.2% |
100,000
-40,000
| -29% | -$4.67M |
|
|
4
IRIDEX
IRIX
$15.1M
| $8.03M | 12.24% |
1,190,000
-130,000
| -10% | -$748K |
|
5
Epsilon Energy
EPSN
$180M
| $5.4M | 8.23% |
1,384,461
| – | – |
|
|
VRS
6
DELISTED
Verso Corporation
VRS
| $5.11M | 7.78% |
350,000
+202,690
| +138% | +$2.67M |
|
|
7
Cigna
CI
$73.3B
| $4.83M | 7.37% |
+20,000
| New | +$4.46M |
|
8
State Street SPDR S&P 500 ETF Trust
SPY
$809B
| $3.96M | 6.04% |
10,000
| – | – |
|
|
BNY
9
Bank of New York Mellon
BNY
$111B
| $3.55M | 5.42% |
75,000
-25,000
| -25% | -$1.1M |
|
|
10
Euronet Worldwide
EEFT
$2.66B
| $1.04M | 1.58% |
+7,500
| New | +$1.08M |
|
11
ATN International
ATNI
$478M
| $442K | 0.67% |
9,000
| – | – |
|
|
12
Wells Fargo
WFC
$269B
| – | – |
-25,000
| Closed | -$755K |
|
Similar funds
TWM
JCA
WH
WPA
PWS
SPC
OC
IVMX
Paragon Associates & Paragon Associates II Joint Venture's Q1 2021 Portfolio in Review
As of Q1 2021, Paragon Associates & Paragon Associates II Joint Venture held 12 positions worth $65.6M, up 0.89% from $65M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
Paragon Associates & Paragon Associates II Joint Venture's Q1 2021 filing shows 2 new, 2 increased, 4 reduced and 1 closed positions. Its largest new stake was Cigna: 20,000 shares worth $4.83M. The largest sale was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $4.67M.
By sector, the portfolio is most concentrated in Healthcare at 35% of assets, up from 32% a quarter earlier, followed by Materials and Energy.
- Paragon Associates & Paragon Associates II Joint Venture's largest Q1 2021 buy was Cigna: 20,000 shares worth $4.83M.
- Paragon Associates & Paragon Associates II Joint Venture added most to Verso Corporation in Q1 2021, an estimated $2.67M increase.
- Paragon Associates & Paragon Associates II Joint Venture's biggest Q1 2021 reduction was Reata Pharmaceuticals, Inc. Class A Common Stock, cutting an estimated $4.67M.
- Paragon Associates & Paragon Associates II Joint Venture fully exited Wells Fargo in Q1 2021, selling an estimated $755K.
- Paragon Associates & Paragon Associates II Joint Venture's ten largest holdings make up 99% of its $65.6M portfolio in Q1 2021.
- Paragon Associates & Paragon Associates II Joint Venture opened 2 new positions and closed 1 in Q1 2021.
- Paragon Associates & Paragon Associates II Joint Venture's portfolio value rose 0.89% quarter-over-quarter to $65.6M.
Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q1 2021, filed 14 May 2021.